North America Companion Diagnostics Market Forecast 2022-2030
Description
North America Companion Diagnostics Market Forecast 2022-2030
KEY FINDINGS
The North America companion diagnostics market is estimated to progress with a 13.41% CAGR across the forecasted period of 2022 to 2030. The rise in the incidence of neurodegenerative conditions, including Alzheimer’s disease, the growing prevalence of chronic diseases, intensifying health consciousness, and the rollout of healthcare plans by the government are among the key factors contributing to the market growth of the region.
MARKET INSIGHTS
The North America companion diagnostics market growth evaluation entails the assessment of Canada and the United States. Various public and private initiatives in the field of companion diagnostics are set to fuel the market growth in Canada. For example, the Alliance for Innovation in Molecular Diagnostics is working towards the improvement of the companion diagnostics innovation environment in Canada. The initiative also aims to minimize the lack of clarity on how decision-makers prioritize companion diagnostics tests by emphasizing interprovincial regulatory as well as operational variability. These factors deter and affect the development and uptake of companion diagnostics, respectively.
In addition, increased investments in R&D expenditure for precision medicine technologies and innovative clinical trials are expected to provide the market in Canada with lucrative growth opportunities. Furthermore, the rollout of healthcare plans for enhanced patient outcomes is anticipated to contribute to the demand and adoption of companion diagnostics in Canada, as well. Therefore, the abovementioned factors are set to drive the market growth in North America during the forecast years.
COMPETITIVE INSIGHTS
The top players operating in the market are Danaher Corporation, Abbott Technologies, Arup Laboratories, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
KEY FINDINGS
The North America companion diagnostics market is estimated to progress with a 13.41% CAGR across the forecasted period of 2022 to 2030. The rise in the incidence of neurodegenerative conditions, including Alzheimer’s disease, the growing prevalence of chronic diseases, intensifying health consciousness, and the rollout of healthcare plans by the government are among the key factors contributing to the market growth of the region.
MARKET INSIGHTS
The North America companion diagnostics market growth evaluation entails the assessment of Canada and the United States. Various public and private initiatives in the field of companion diagnostics are set to fuel the market growth in Canada. For example, the Alliance for Innovation in Molecular Diagnostics is working towards the improvement of the companion diagnostics innovation environment in Canada. The initiative also aims to minimize the lack of clarity on how decision-makers prioritize companion diagnostics tests by emphasizing interprovincial regulatory as well as operational variability. These factors deter and affect the development and uptake of companion diagnostics, respectively.
In addition, increased investments in R&D expenditure for precision medicine technologies and innovative clinical trials are expected to provide the market in Canada with lucrative growth opportunities. Furthermore, the rollout of healthcare plans for enhanced patient outcomes is anticipated to contribute to the demand and adoption of companion diagnostics in Canada, as well. Therefore, the abovementioned factors are set to drive the market growth in North America during the forecast years.
COMPETITIVE INSIGHTS
The top players operating in the market are Danaher Corporation, Abbott Technologies, Arup Laboratories, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
134 Pages
- 1. Research Scope & Methodology
- 1.1. Study Objectives
- 1.2. Scope Of Study
- 1.3. Methodology
- 1.4. Assumptions & Limitations
- 2. Executive Summary
- 2.1. Market Size & Estimates
- 2.2. Market Overview
- 3. Market Dynamics
- 3.1. Key Drivers
- 3.1.1. Growing Number Of Cancer Cases And Mortalities
- 3.1.2. Increasing Popularity Of Precision Medicines
- 3.1.3. Rising Number Of Adverse Drug Reaction Cases
- 3.2. Key Restraints
- 3.2.1. Country-specific Reimbursement Issues
- 3.2.2. Frequent Cases Of Leakage In Companion Diagnostics For Oncology
- 4. Key Analytics
- 4.1. Impact Of Covid-19 On Companion Diagnostics Market
- 4.2. Key Market Trends
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Buyers Power
- 4.3.2. Suppliers Power
- 4.3.3. Substitution
- 4.3.4. New Entrants
- 4.3.5. Industry Rivalry
- 4.4. Opportunity Matrix
- 4.5. Vendor Landscape
- 4.6. Value Chain Analysis
- 4.7. Key Buying Criteria
- 4.8. Regulatory Framework
- 5. Market By Technology
- 5.1. In Situ Hybridization
- 5.2. Polymerase Chain Reaction
- 5.3. Immunohistochemistry
- 5.4. Next Generation Sequencing
- 5.5. Other Technologies
- 6. Market By Indication
- 6.1. Oncology
- 6.2. Neurology
- 6.3. Infectious Diseases
- 6.4. Other Indications
- 7. Market By End-user
- 7.1. Pharmaceutical And Biopharmaceutical Companies
- 7.2. Reference Laboratories
- 7.3. Other End-users
- 8. Market By Products & Services
- 8.1. Assay Kits And Reagents
- 8.2. Software & Services
- 9. Geographical Analysis
- 9.1. North America
- 9.1.1. Market Size & Estimates
- 9.1.2. Key Growth Enablers
- 9.1.3. Key Challenges
- 9.1.4. Key Players
- 9.1.5. Country Analysis
- 9.1.5.1. United States
- 9.1.5.2. Canada
- 10. Competitive Landscape
- 10.1. Key Strategic Developments
- 10.1.1. Mergers & Acquisitions
- 10.1.2. Product Launches & Developments
- 10.1.3. Partnerships & Agreements
- 10.2. Company Profiles
- 10.2.1. Abbott Laboratories
- 10.2.2. Agilent
- 10.2.3. Alamc Group
- 10.2.4. Arup Laboratories
- 10.2.5. Biocartis
- 10.2.6. Biomerieux Sa
- 10.2.7. Danaher Corporation
- 10.2.8. Ge Healthcare
- 10.2.9. Genomic Health
- 10.2.10. Illumina Inc
- 10.2.11. Myriad Genetics Inc
- 10.2.12. Qiagen Nv
- 10.2.13. Roche Diagnostics
- 10.2.14. Sysmex Corporation
- 10.2.15. Thermo Fisher Scientific Inc
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
